ST. JOSEPH, Mich., March 17 /PRNewswire/ -- GeneGo, Inc., the leading provider of pathway data mining & analysis solutions, today announced a license agreement with Entelos of Foster City, CA, a company specializing in predictive technologies, including toxicogenomics and PhysioLab(R) virtual human disease models. GeneGo will use Entelos' DrugMatrix(R) gene expression data to further develop GeneGo's Functional Descriptor predictive toxicology models.
"Access to a comprehensive, pharmacologically-diverse and fully annotated compendium of gene expression data is critical to developing high-performance predictive models," said Richard Brennan, Director of Toxicology at GeneGo. "This is one of the key goals of our MetaTox partnership. DrugMatrix is the largest toxicogenomic database available, and will allow us to apply the lessons we have learned from our participation in the Microarray Quality Control Consortium to expand our collection of biological pathway-based classifiers with toxicity models for a wide variety of adverse drug effects in key target tissues."
"We are very pleased to be working with GeneGo and participating in their MetaTox projects," said Alan Roter, VP of Informatics at Entelos. "GeneGo's unique approach of generating functional descriptors is a great complement to the classifiers and predictive models in DrugMatrix, and we see great benefit to the scientific community using predictive toxicogenomics."
About GeneGo, Inc.
GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 5.2(TM), assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 5.2(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore.
For more information, please visit the company's web site at www.genego.com.
About Entelos, Inc.
Entelos, Inc. is a US-based life sciences company applying next-generation predictive technologies to revolutionize the way medicines are discovered, developed, and utilized. The Company leverages its proprietary in silico disease models, "virtual human" technology, and toxicology reference systems to develop safer and more effective drugs, improve the quality of health-related consumer products, and deliver on the promise of personalized medicine. Entelos provides customized products, technology and research services to global pharmaceutical, health-care, and consumer products companies in safety testing, arthritis, cardiovascular diseases, asthma, obesity, diabetes, hematopoeisis (anemia), cholesterol metabolism, skin sensitization, and personal care products.
For more information, please visit the company's web site at www.entelos.com
CONTACT: Julie Bryant, VP Business Development and Marketing of GeneGo,
Inc., +1-858-756-7996, email@example.com
Web site: http://www.genego.com/